Stephen Harrison joins Louise Campbell and Roger Green for an insight-laden episode about challenges and opportunities in NASH drug development.
This final conversation unpacks a stimulating deep dive into the science and strategy behind quantitating and reducing hepatocellular ballooning. As for the closing question, Roger asks what will be the biggest difference to emerge in trial execution design over the next two years. Stephen begins his response with the suggestion that AI-assisted pathology could one day be a potential surrogate endpoint. Tune in to find out how and why.
If you enjoy the episode, have questions or interest around NASH therapeutic development, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!